Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 200.00 GBp
Change Today 0.00 / 0.00%
Volume 0.0
INS On Other Exchanges
As of 11:35 AM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

instem plc (INS) Snapshot

200.00 GBp
Previous Close
200.00 GBp
Day High
200.00 GBp
Day Low
200.00 GBp
52 Week High
05/18/15 - 212.50 GBp
52 Week Low
11/25/14 - 123.50 GBp
Market Cap
Average Volume 10 Days
0.01 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for INSTEM PLC (INS)

Related News

No related news articles were found.

instem plc (INS) Related Businessweek News

No Related Businessweek News Found

instem plc (INS) Details

Instem plc provides information technology solutions to the early development healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include Provantis, an integrated Windows-based system for organizations and universities engages in non-clinical evaluation studies; ALPHADAS, an eSource, pro-active EDC system for early phase clinical trials; TRP, which provides toxicology solution for pharmaceutical, chemical, and contract research laboratory corporations; DISPENSE, a computer based system for test item control; Logbook, a solution to replace GLP and Non-GLP paper data; Submit, an integrated nonclinical solution suite; and SENDView, an application that simplifies the review of SEND datasets. The company also offers Animal Care Information System, an animal management software solution; Centrus, a solution suite that provides early drug development information from various sources; Safety Intelligence Program, a Web-based database of toxicology and pathology intelligence; SRS, a data integration platform; Metawise, an ontology solution; and OmniViz, a data mining and visual analytics tool. In addition, it offers a range of services comprising project management, installation, validation, data management, training, solution development, remote systems, client support, and specialized solutions. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.

130 Employees
Last Reported Date: 04/27/15
Founded in 1969

instem plc (INS) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 144.0K GBP
Chief Financial Officer, Secretary and Execut...
Total Annual Compensation: 100.0K GBP
Compensation as of Fiscal Year 2014.

instem plc (INS) Key Developments

Instem plc Wins Three Contracts for ALPHADAS Product Suite

Instem plc announced that it has won three contracts for its ALPHADAS product suite worth approximately £1.4 million. The three new contract wins across mainland Europe, Canada and the USA comprise two new customers and an expansion contract with an existing customer. Instem will deploy the ALPHADAS product suite on one additional site for the existing customer and across eight sites with the two new customers. As the majority of the total £1.4 million contract value comprises perpetual license fees, professional services and ongoing maintenance, it is expected that most of this revenue will be recognised in the current financial year.

Instem plc, Annual General Meeting, May 19, 2015

Instem plc, Annual General Meeting, May 19, 2015., at 12:00 GMT Standard Time. Location: at the offices of Baker Tilly.

Instem plc Reports Unaudited Consolidated Earnings Results for the Year Ended December 31, 2014

Instem plc reported unaudited consolidated earnings results for the year ended December 31, 2014. For the year, revenue was GBP 13,429,000 against GBP 11,361,000 a year ago. Profit from operation was GBP 562,000 against GBP 760,000 a year ago. Profit before taxation was GBP 212,000 against GBP 698,000 a year ago. Profit for the year attributable to the owner of the parent company was GBP 150,000 or 1.2 pence per basic and diluted share against GBP 529,000 or 4.5 pence per basic and diluted share a year ago. Net cash generated from operating activities was GBP 482,000 against GBP 1,953,000 a year ago. Purchase of property, plant and equipment was GBP 124,000 against GBP 171,000 a year ago. Purchase of intangible assets was GBP 369,000 against GBP 407,000 a year ago. Adjusted diluted earnings per share were 8.3 pence compared to 8.6 pence a year ago. Adjusted EBITDA amounted to GBP 1,857,000 compared to GBP 1,772,000 a year ago. The organic revenue growth was driven primarily from the increased sales of Submit suite with total revenue benefiting from a full year contribution from the Perceptive Instruments acquisition, which made negligible revenue contribution in 2013. Revenues were increased 18%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INS:LN 200.00 GBp 0.00

INS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INS.
View Industry Companies

Industry Analysis


Industry Average

Valuation INS Industry Range
Price/Earnings 100.0x
Price/Sales 1.8x
Price/Book 4.5x
Price/Cash Flow 22.9x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSTEM PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at